# Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Source: https://onco.cc/trials/nct05466149/  
OnCo record `nct05466149` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion is a phase 2 interventional study registered as NCT05466149 by Allist Pharmaceuticals, Inc., with 100 participants enrolled, started 2022-09-27 and due to reach its primary completion in 2025-06-27. Interventions recorded: Furmonertinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05466149
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
- Sponsor: Allist Pharmaceuticals, Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05466149: https://clinicaltrials.gov/study/NCT05466149

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)

---
JSON: https://onco.cc/api/v1/entities/nct05466149.json